top of page

What's Slowing Medical Cannabis Clinical Research?

CU scientists hail recent supply expansion as game-changer in drive for evidence-based care

Despite the urgency for rigorous clinical research on medical marijuana, government red tape has slowed progress and tied scientists’ hands. CU Anschutz researchers discuss the need for their pioneering efforts and applaud a new development that could speed progress in the emerging field.

Artin (Art) Shoukas, PhD, a Johns Hopkins University professor emeritus, would have never dreamed he’d be using marijuana every night in his retirement years. He melts the medicinal form – mostly cannabidiol (CBD) with just a touch of tetrahydrocannabinol (THC) – under his tongue before dinner.

It helps him sleep. But not just because of its reported slumber-inducing effects. He takes a full-spectrum, cannabis-based product to calm his legs.

Diagnosed with restless legs syndrome (RLS) in 1991, when the relentless feeling of “ants crawling” inside his legs became intense and life-altering, Shoukas tried everything his doctor at Johns Hopkins suggested. Iron supplements. Quinine. Eventually, he resorted to OxyContin after finding it helped his RLS following an unrelated surgical procedure.

The opioid worked. But the professor of physiology and biomedical engineering knew the drug class behind a nationwide health crisis wasn’t a sustainable answer. Then he found Jacquelyn (Jacci) Bainbridge, PharmD, a professor at the University of Colorado Anschutz Medical Campus.

Bainbridge, a professor in the Skaggs School of Pharmacy and Pharmaceutical Sciences, helps conduct cannabis-related clinical trials on campus and educates students and consumers on the growing need for evidence-based facts.

‘Does it work for everybody?’

“I started to get worried about the use of OxyContin,” Shoukas said. “It’s habit-forming. So I tried to come off it, and I did. But the RLS came back, and it was instantaneous.”

In search of an alternative, Shoukas went to the RLS Foundation website, where he spotted a webinar by Bainbridge on CBD effects. She and colleagues study cannabis for medicinal uses, including groundbreaking investigations led by Emily Lindley, PhD, and Rachael Rzasa Lynn, MD, into using cannabis as an opioid alternative.

After much trial and error working closely with Bainbridge and his healthcare provider, Shoukas’s “itchy, twitchy” legs are still. He doesn’t promote other people experimenting with cannabis on their own. But he’s excited about the related research taking place on the CU Anschutz Medical Campus that might lead to other patients finding cannabis-therapy success.

“It actually is more effective,” Shoukas said of his CBD-based therapy compared to the opioid. “This is very individualized, though. As my colleague (Bainbridge) says, cannabis comes from a plant,” Shoukas said. “It depends on where it’s grown, how it’s grown, what time of the year it’s harvested and how it’s processed.

"It’s not a pharmacological agent (except for Epidiolex®, FDA approved for certain types of epilepsy) where you give a strict formula for it. It’s a plant. Does it work? Works for me. Does it work for everybody? I’d like to know.”

It’s one of many questions Bainbridge and colleagues have been trying to answer since becoming the first university in the state to launch cannabis clinical trials in 2016. Can cannabis reduce opioid use? Can it work with other issues, from Parkinson’s disease to back pain? Does THC improve the effects of CBD or other cannabinoids? What are the potential side effects and serious drug contraindications consumers need to know?

As cannabis legalization progresses, and product marketing surges across the country, many states and universities are seeking to address the questions regarding cannabis’ clinical applicability, but it isn’t easy.

Patient use fuels research drive

After Colorado and Washington became the first states to open marijuana dispensary doors to recreational use in 2012, many people began experimenting with cannabis to ease ailments, said Maureen Leehey, MD, a University of Colorado School of Medicine neurology professor and one of the first researchers on campus to launch cannabis trials.

“My Parkinson’s patients are usually in their 60s and 70s, and their adult children were telling them: You should give this a try,” Leehey said. Of those patients who did try cannabis, some reported improved symptoms, from better sleep to reduced tremors; however, others described bad experiences, including hallucinations, dizziness, nausea and sleep disturbances, she said.

“That’s what stimulated us,” Leehey said of herself and her colleagues, who wanted to protect their patients while providing evidence-based care.

“We need to know: Is it effective, and is it safe?” said Bainbridge, also a professor in the Department of Neurology, who works closely with Leehey. “We need answers to these questions, answers that we can only get through clinical research.”

Hurdles stall clinical studies

Winning the government green light for clinical trials at the CU Anschutz Medical Campus took two years after Lindley and Leehey received the Colorado Department of Public Health and Environment first-ever grants for cannabis clinical trials in 2014.

The Drug Enforcement Agency (DEA) has strict licensing regulations for providers to dispense cannabis and complex requirements for securing cannabis products at the facility conducting the clinical trials – which the university worked hard to make happen, Leehey said.

But one of the biggest hurdles Leehey and medical scientists across the country have faced is a government restriction on the cannabis supply they can use. Since 1968, researchers have been limited to only one cannabis supplier: a National Institute of Drug Abuse (NIDA)-contracted facility at the University of Mississippi. “It wasn’t supplying the full gamut of products that we needed,” Leehey said.

The constraint has delayed moving forward with clinical trials involving the use of cannabis and slowed progression of publishing evidence-based data establishing efficacy and safety parameters.

Now, after years of pressure on the government to open the door to more manufacturers, the restriction is lifting. This past year, the DEA announced it was in the process of approving more domestic manufacturers. “I think it’s going to be any day now that we can get the products,” Leehey said.

The move, she said, will be a game-changer for cannabis-related studies.

“It means everything to me as a researcher. I need a good variety of products. These other companies are producing a much better range of types of products, combinations of different components of cannabis and different methods of delivery.”

Strains and delivery method matter

Studying varying strains, or chemovars, is important, especially as the types of cannabis consumers are getting from dispensaries today are far more diverse and potent than cannabis of the past.

“I know exactly what’s inside of it,” Shoukas said of the pills he gets from a “highly-controlled” provider. “With most cannabis products, you don’t know what you’re getting,” he said, emphasizing the need for clinical trials.

“Even if it’s a pharmacological agent, you still need to do clinical trials, because everybody’s different. You don’t know what the reaction is going to be for a lot of agents. It gets worse with cannabis, because there’s really no fixed control over what you are doing and what you are getting.”

Mode of delivery also matters, Bainbridge said. “Products are absorbed differently, depending on how they’re consumed. So, is it an edible? Is it oral? Is it smoked? Is it vaporized?”

Read full article



108 views0 comments
bottom of page